MétaCan
Menu
Back to cohort
Record W4407115522 · doi:10.1016/j.jhep.2025.01.013

Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

2025· article· en· W4407115522 on OpenAlexaff
Homie Razavi, Imam Waked, Huma Qureshi, Loreta A. Kondili, Ann‐Sofi Duberg, Soo Aleman, Junko Tanaka, Jeffrey V. Lazarus, Daniel Low‐Beer, Zaigham Abbas, Antoine Abou Rached, Alessio Aghemo, Inka Aho, Ulus Salih Akarca, Said A. Al‐Busafi, Waleed K. Al‐Hamoudi, Khalid Al‐Naamani, Ahmed Sabry Alaama, Manahil M Aldar, Mohammed Alghamdi, Mónica Alonso González, Haleema Alserehi, Anil C. Anand, Tarik Asselah, Abdullah M. Assiri, Kostas Athanasakis, Rita Atugonza, Ziv Ben‐Ari, Thomas Berg, Carlos Eduardo Brandão‐Mello, A. Brown, Kimberly Brown, Robert S. Brown, Philip Bruggmann, Maurizia Rossana Brunetto, María Buti, Hugo Cheinquer, Peer Brehm Christensen, Vladimir Chulanov, Laura Garza, Carla S. Coffin, Nicola Coppola, Antonio Craxı̀, Javier Crespo, Fuqiang Cui, Olav Dalgård, Alethse de la Torre, Victor de Lédinghen, Douglas T. Dieterich, Sylvia Dražilová, Jean‐François Dufour, Mohamed El‐Kassas, Mohammed Elbadri, Gamal Esmat, Rafael Esteban Mur, Brandon Eurich, Diana Faini, Paulo Roberto Abrão Ferreira, Robert Flisiak, Soňa Fraňková, Giovanni Battista Gaeta, Ivane Gamkrelidze, Edward Gane, Virginia Garcia, Javier García‐Samaniego, Manik Gemilyan, Magnús Gottfreðsson, Michael Gschwantler, Ana Paula Maciel Gurski, Behzad Hajarizadeh, Saeed Hamid, Angelos Hatzakis, Julian Hercun, Ivana Hockicková, Jee‐Fu Huang, Béla Hunyady, Sharon Hutchinson, Naoko Ishikawa, Kiyohiko Izumi, Antonio Izzi, Martin Janíčko, Peter Jarčuška, Agita Jēruma, Asgeir Johannessen, Kulpash Kaliaskarova, Jia‐Horng Kao, Knut Boe Kielland, Nicolas Kodjoh, Shyamasundaran Kottilil, Pavol Kristián, Paul Y. Kwo, Martin Lagging, Hilton Y. Lam, Pablo Lázaro, Mei‐Hsuan Lee, Sabela Lens, Valentina Liakina, Young‐Suk Lim, Michael Makara, M.P. Manns, Casimir Manzengo, Sadik Memon, Maria Cássia Mendes-Corrêa, Vincenzo Messina, Håvard Midgard, Niamh Murphy, Erkin Musabaev, Marcelo Contardo Moscoso Naveira, H. Nde, Francesco Negro, Nirada Nim, Ponsiano Ocama, Sigurður Ólafsson, C. Omuemu, Javier Pamplona, Calvin Q. Pan, George Papatheodoridis, Nikolay Pimenov, Hossein Poustchi, Maria Giovanna Quaranta, Alnoor Ramji, Henna Rautiainen, Devin Razavi‐Shearer, Kathryn Razavi‐Shearer, Ezequiel Ridruejo, Cielo Ríos, Shakhlo Sadirova, Faisal M. Sanai, Christoph Sarrazin, Gulya Sarybayeva, Ivan Schréter, Carole Seguin‐Devaux, Leandro Soares Sereno, Gamal Shiha, Josie Smith, Riham Soliman, Mark Sonderup, C Wendy Spearman, Rudolf Stauber, Catherine Stedman, Vana Sypsa, Frank Tacke, Norah A. Terrault, Ieva Tolmane, Berend Van Welzen, Alexis Voeller, Yasir Waheed, Carolyn Wallace, Robert Whittaker, Vincent Wai‐Sun Wong, Magdalena Ydreborg, Kakharman Yesmembetov, Ming‐Lung Yu, Stefan Zeuzem, Eli Zuckerman

Bibliographic record

VenueJournal of Hepatology · 2025
Typearticle
Languageen
FieldMedicine
TopicHepatitis C virus research
Canadian institutionsUniversity of British ColumbiaCentre Hospitalier de l’Université de MontréalUniversity of Calgary
FundersDivision of Materials ResearchEuropean CommissionJoseph C. Monastra Foundation for Pancreatic Cancer ResearchAbbVieCalifornia Dental Association FoundationWorld Health OrganizationPan American Health OrganizationGilead Sciences
KeywordsVirologyHepatitis D virusHepatitis B virusMedicineVirusHepatitis a virus

Abstract

fetched live from OpenAlex

BACKGROUND & AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV). Monitoring HCV treatment trends by country, region, and globally is important to assess progress toward the World Health Organization's 2030 elimination targets. Additionally, historical patterns can help predict the uptake of future therapies for other liver diseases. METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used. RESULTS: An estimated 13,816,000 (95% uncertainty intervals: 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program. CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region, which may not reflect a lower prevalence but may instead reflect the diminishing returns of existing strategies. IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.044
Threshold uncertainty score0.997

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.384
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations18
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of HepatologySame topicHepatitis C virus researchFrench-language works237,207